US 12,329,815 B2
Acoustic driven drug delivery systems
John Noble James Reynolds, Dunedin (NZ); Eng Wui Tan, Dunedin (NZ); Brian Ian Hyland, Dunedin (NZ); Guy Nicholas Louis Jameson, Dunedin (NZ); Maung Mo Aung Myint, Dunedin (NZ); Sean Marshall Mackay, Dunedin (NZ); and Jeffery Russell Wickens, Okinawa (JP)
Assigned to University of Otago, Dunedin (NZ)
Filed by UNIVERSITY OF OTAGO, Dunedin (NZ)
Filed on Jan. 20, 2022, as Appl. No. 17/579,832.
Application 17/579,832 is a continuation of application No. 15/754,081, granted, now 11,260,126, previously published as PCT/NZ2016/050130, filed on Aug. 19, 2016.
Claims priority of application No. 2015903387 (AU), filed on Aug. 21, 2015.
Prior Publication US 2022/0143182 A1, May 12, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 41/00 (2020.01); A61K 9/00 (2006.01); A61K 9/127 (2006.01); A61K 9/51 (2006.01)
CPC A61K 41/0028 (2013.01) [A61K 9/0009 (2013.01); A61K 9/127 (2013.01); A61K 9/5115 (2013.01); Y10S 977/773 (2013.01); Y10S 977/906 (2013.01); Y10S 977/907 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A method of treating one or more of primary or secondary cancer, Parkinson's disease, and epilepsy, by delivering a therapeutic agent to a patient in need thereof, comprising:
administering to a patient a therapeutic formulation comprising a therapeutic agent and liposomes with hollow gold nanostructures tethered to the liposomes; and
applying a pulsed ultrasound signal to the liposomes in the patient's brain, whereby the pulsed ultrasound signal delivers a stepwise release of the therapeutic agent from the liposome composition, wherein the ultrasound signal has a frequency between about 200 kHz and 1 MHZ, and wherein the ultrasound signal's intensity is between about 0.01 and 10 W/cm2
wherein when the disease treated is primary or secondary cancer, the therapeutic agent is an anti-cancer agent or an antineoplastic agent;
wherein when the disease to be treated is Parkinson's disease, the therapeutic agent is an agent capable of treating Parkinson's disease; and
wherein when the disease to be treated is epilepsy, the therapeutic agent is capable of treating epilepsy.